Pharmaceutical Executive
December 01, 2010
0
0
After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation
December 01, 2010
0
0
After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation
December 01, 2010
Feature
0
0
A small company shows how it can play a major role in a relatively short time frame
December 01, 2010
0
0
How to achieve distribution diversification in a small market
December 01, 2010
0
0
With a fiercely competitive spirit and grand ambitions that reach far beyond Taiwan, Standard is showing that it is far from the middle-of-the-road company its name implies
December 01, 2010
Columns
0
0
The simpler the explanation of a disorder and its treatment, the better able a patient is to take proper care of himself
December 01, 2010
Columns
0
0
Being strategic-and applying data tools effectively- will go along way in helping to produce analytics that drive sales
December 01, 2010
Columns
0
0
Healthcare marketing in today's post-recession economy is not about one-size-fits-all vehicles, but rather about bringing your prouct into consumers' lives in a series of personal, non-invasive ways
December 01, 2010
Columns
0
0
The new investigative journalism organization recently took an in-depth look at pharma with its "Dollars for Docs" report. In return, Pharm Exec takes a look back at ProPublica
December 01, 2010
From the Editor
0
0
The end of anther year is an appropriate time to highlight the march of time-and the transitions that accompany it
December 01, 2010
Columns
0
0
Stepped-up enforcement of the Foreign Corrupt Practices Act requires enhanced global coordination of compliance
December 01, 2010
Columns
0
0
Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine
December 01, 2010
Features
0
0
Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office
December 01, 2010
Features
0
0
42 of the best new drugs in development–or parked at the FDA
December 01, 2010
Features
0
0
Pharma sets the pace for China's ambitious new innovation agenda
December 01, 2010
Columns
0
0
The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?
December 01, 2010
Columns
0
0
Cegedim survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spend
December 01, 2010
Features
0
0
Pharm Exec's Pipeline Report 2018